Mumbai, December 03, 2025: Corona Remedies Ltd is set to open its Initial Public Offering (IPO) on Monday, December 08, 2025, with the issue closing on December 10. The pharmaceutical company has fixed a price band of ₹1,008–₹1,062 per equity share, while eligible employees will receive a discount of ₹54 per share. The Anchor Investor bidding will take place on December 05.
The IPO is entirely an Offer for Sale (OFS), aggregating up to ₹6,553.71 crore, with shares being sold by promoter group members and investor shareholders including Sepia Investments, Anchor Partners and Sage Investment Trust. Investors can bid for a minimum of 14 shares and in multiples thereafter. JM Financial, IIFL Capital Services and Kotak Mahindra Capital are the book-running lead managers for the offer.
Corona Remedies is a fast-growing branded pharmaceutical company, active in women’s healthcare, cardio-diabeto, pain management and urology segments. The company operates a portfolio of 71 brands as of June 2025. According to CRISIL, it is the fastest-growing company among the top 30 players in the Indian Pharmaceutical Market for the period MAT June 2024–MAT June 2025.
The IPO is being launched through the Book Building Process, with allocations for QIBs, NIIs and retail investors as per SEBI norms. The equity shares are proposed to be listed on both the NSE and BSE, marking a significant step in the company’s expansion within India’s pharmaceutical sector.
